SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...

Please provide your email address to receive an email when new articles are posted on . Among patients who received implantable cardioverter defibrillator therapy, a subcutaneous vs. transvenous ...

The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and ...

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

For older patients without an indication for pacing, the subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) provides results comparable to those seen with traditional ...

Though the PRAETORIAN group was technically unable to prove that 8 years was enough to give a subcutaneous implantable cardioverter-defibrillator (ICD) an edge in safety, complication rates helped ...

Electric shocks delivered by subcutaneous defibrillators are equally effective compared to shocks delivered by conventional transvenous defibrillators, according to a study published in the journal ...

The 2025 Appropriate Use Criteria for implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT), and pacing have been released. This year’s guideline is broader than ...